Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
48.16 USD | +2.24% | -3.69% | +348.70% |
May. 08 | Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating | MT |
May. 08 | Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Business Summary
Number of employees: 68
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Immunotherapies
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -6.14% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 9 | 100.0 % | 8 | 100.0 % | -6.14% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 17-05-31 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 18-04-30 | |
Charles Winter
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Andy Meyer
IRC | Investor Relations Contact | 40 | 21-02-28 |
James Pennington
LAW | General Counsel | - | - |
Human Resources Officer | - | 22-09-22 | |
Byron Robinson
PRN | Corporate Officer/Principal | 59 | 22-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 21-03-17 |
Jay Lichter
CHM | Chairman | 62 | 17-05-31 |
Director/Board Member | 68 | 21-09-06 | |
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Alana McNulty
BRD | Director/Board Member | 61 | 21-09-06 |
Sheila Gujrathi
BRD | Director/Board Member | 53 | 21-03-17 |
Winston Kung
BRD | Director/Board Member | 48 | 22-09-21 |
Jake Simson
BRD | Director/Board Member | 38 | 21-02-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 51,856,438 | 46,924,527 ( 90.49 %) | 5,771 ( 0.0111 %) | 90.49 % |
Company contact information
Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway Suite 200
92130, San Diego
+
http://www.januxrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+348.70% | 2.44B | |
+42.87% | 50.93B | |
-0.46% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.10% | 26.02B | |
-21.87% | 18.9B | |
+7.67% | 13.21B | |
+23.99% | 12.17B | |
+30.18% | 12.16B |
- Stock Market
- Equities
- JANX Stock
- Company Janux Therapeutics, Inc.